Rosetta launches first microRNA-based test
This article was originally published in Clinica
Rosetta Genomics has launched its first microRNA-based diagnostic, miRview, which will be available through the firm's CLIA-certified laboratory in Philadelphia, Pennsylvania. The test differentiates squamous from non-squamous non-small cell lung cancer (NSCLC); this is important because certain drugs, such as Genentech/Roche's Avastin (bevacizumab), are less effective in squamous cell disease. In extreme cases, fatal bleeding can occur in squamous cell patients given these drugs. miRview received its first CLIA approval from the New York State Department of Health in July 2008 (see Clinica No 1317, p 18). The test has a sensitivity and specificity of 97% and 91%, respectively, in identifying squamous cell NSCLC, Rehovot, Israel-based Rosetta said.